[{"address1": "Dr. Neergaards Vej", "address2": "5th Floor", "city": "Horsholm", "zip": "2970", "country": "Denmark", "phone": "45 53 53 18 50", "website": "https://www.evaxion-biotech.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.", "fullTimeEmployees": 63, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Kanstrup M.Sc.", "age": 51, "title": "Chief Executive Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 454000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andreas Holm Mattsson", "age": 47, "title": "Co-Founder and Chief AI & Culture Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 247000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Niels Iversen Moller M.D.", "age": 44, "title": "Co-Founder, VP of Business & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 120000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jesper Nyegaard Nissen M.Sc.", "age": 52, "title": "CFO & COO", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 346967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Birgitte  Rono Ph.D.", "age": 46, "title": "Chief Scientific Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 336000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. J\u00fcrgen  Langh\u00e4rig EMBA, Ph.D.", "title": "Head of Business Development & Member of Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.02, "open": 3.12, "dayLow": 2.8609, "dayHigh": 3.12, "regularMarketPreviousClose": 3.02, "regularMarketOpen": 3.12, "regularMarketDayLow": 2.8609, "regularMarketDayHigh": 3.12, "beta": -0.003, "forwardPE": -0.7813333, "volume": 40585, "regularMarketVolume": 40585, "averageVolume": 693914, "averageVolume10days": 56410, "averageDailyVolume10Day": 56410, "bid": 2.98, "ask": 3.05, "bidSize": 900, "askSize": 3100, "marketCap": 14097871, "fiftyTwoWeekLow": 2.8609, "fiftyTwoWeekHigh": 18.5, "fiftyDayAverage": 5.64842, "twoHundredDayAverage": 9.029805, "currency": "USD", "enterpriseValue": 130133464, "floatShares": 34541359, "sharesOutstanding": 4811560, "sharesShort": 19395, "sharesShortPriorMonth": 11668, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.004, "heldPercentInsiders": 0.17992, "heldPercentInstitutions": 0.01012, "shortRatio": 0.03, "bookValue": -0.983, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -24474000, "trailingEps": -9.5, "forwardEps": -3.75, "enterpriseToEbitda": -5.508, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "EVAX", "underlyingSymbol": "EVAX", "shortName": "Evaxion Biotech A/S", "longName": "Evaxion Biotech A/S", "firstTradeDateEpochUtc": 1612535400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "10e58503-7bd5-32f9-974e-d651a4f9f505", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.93, "targetHighPrice": 20.0, "targetLowPrice": 14.0, "targetMeanPrice": 18.0, "targetMedianPrice": 20.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 2605000, "totalCashPerShare": 0.064, "ebitda": -23624750, "totalDebt": 10306000, "quickRatio": 0.722, "currentRatio": 1.462, "operatingCashflow": -21515000, "financialCurrency": "USD", "trailingPegRatio": null}]